MGX-001 — IND submission
4Q 2026
Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia ASource filing
MGX biotech catalysts & pipeline
METAGENOMI THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
MGX-001 — NDA/BLA submission
4Q 2026
MGX-001 on track for IND/CTA submissions in 4Q 2026Source filing